ATE548046T1 - Therapeutische verwendung von pulver von dunaliella - Google Patents

Therapeutische verwendung von pulver von dunaliella

Info

Publication number
ATE548046T1
ATE548046T1 AT04019206T AT04019206T ATE548046T1 AT E548046 T1 ATE548046 T1 AT E548046T1 AT 04019206 T AT04019206 T AT 04019206T AT 04019206 T AT04019206 T AT 04019206T AT E548046 T1 ATE548046 T1 AT E548046T1
Authority
AT
Austria
Prior art keywords
therapeutic use
dunaliella powder
subject
powder
dunaliella
Prior art date
Application number
AT04019206T
Other languages
German (de)
English (en)
Inventor
Aviv Shaish
Dror Harats
Original Assignee
Nikken Sohonsha Corp
Tel Hashomer Medical Res Infrastructure & Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikken Sohonsha Corp, Tel Hashomer Medical Res Infrastructure & Services Ltd filed Critical Nikken Sohonsha Corp
Application granted granted Critical
Publication of ATE548046T1 publication Critical patent/ATE548046T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04019206T 2003-09-24 2004-08-12 Therapeutische verwendung von pulver von dunaliella ATE548046T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/668,601 US7264813B2 (en) 2003-09-24 2003-09-24 Therapeutic uses of Dunaliella powder

Publications (1)

Publication Number Publication Date
ATE548046T1 true ATE548046T1 (de) 2012-03-15

Family

ID=34313520

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04019206T ATE548046T1 (de) 2003-09-24 2004-08-12 Therapeutische verwendung von pulver von dunaliella

Country Status (5)

Country Link
US (3) US7264813B2 (OSRAM)
EP (2) EP1522310B1 (OSRAM)
JP (5) JP5020463B2 (OSRAM)
AT (1) ATE548046T1 (OSRAM)
IL (1) IL162987A (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007210917A (ja) * 2006-02-08 2007-08-23 Kochi Univ 脂肪細胞縮小化剤、医薬品及び飲食品
US20090169586A1 (en) * 2006-03-24 2009-07-02 Ian Simon Tracton Stable packaged dosage form and process therefor
JP2008222555A (ja) * 2007-03-08 2008-09-25 Nagasakiken Koritsu Daigaku Hojin アディポネクチン受容体発現増加剤
WO2009105048A2 (fr) * 2008-02-19 2009-08-27 Rached Smida Nouvelles applications du hdl reconstitué
WO2009133552A2 (en) * 2008-04-29 2009-11-05 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
US20100303989A1 (en) 2008-10-14 2010-12-02 Solazyme, Inc. Microalgal Flour
JP5733592B2 (ja) * 2008-10-20 2015-06-10 株式会社日健総本社 脂質異常治療薬の副作用防止物質
US8747834B2 (en) 2009-03-03 2014-06-10 Solazyme, Inc. Methods of treating impaired glucose metabolism via administration of algal biomass
WO2011070568A1 (en) * 2009-12-10 2011-06-16 Nikken Sohonsha Corporation Method for treating psoriasis
US9577089B2 (en) 2010-03-02 2017-02-21 Vishay-Siliconix Structures and methods of fabricating dual gate devices
US10098371B2 (en) 2013-01-28 2018-10-16 Solazyme Roquette Nutritionals, LLC Microalgal flour
FR3009619B1 (fr) 2013-08-07 2017-12-29 Roquette Freres Compositions de biomasse de microalgues riches en proteines de qualite sensorielle optimisee
GB201718822D0 (en) 2017-11-14 2017-12-27 Univ Greenwich Production of dunaliella
JP6947665B2 (ja) * 2018-03-13 2021-10-13 アイカ工業株式会社 光硬化性粘着樹脂組成物
WO2020202152A1 (en) * 2019-04-01 2020-10-08 Tel Hashomer Medical Research Infrastructure And Services Ltd. Dunaliella alga preparation for prevention and/or treatment of a neurodegenerative disease, a disorder associated with protein misfolding and cognitive decline

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199895A (en) 1977-05-25 1980-04-29 Yeda Research And Development Co. Ltd. Production of glycerol, carotenes and algae meal
USPP4511P (en) 1978-06-26 1980-03-18 Yeda Research & Development Co. Ltd. Alga strain
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
US4915965A (en) * 1988-02-25 1990-04-10 Yoshio Tanaka Process for production of encapsulated foodstuff containing dunaliella algae
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5219888A (en) 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
EP0643692B1 (en) 1992-06-04 1999-11-24 Betatene Pty. Ltd. High cis beta-carotene composition
US6262109B1 (en) * 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
DK0859608T3 (da) 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister
WO1997010813A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
IL119224A (en) 1996-09-09 2002-11-10 Hadasit Med Res Service Medicament for protection from effects of irradiation
JP3037628B2 (ja) * 1997-03-06 2000-04-24 マイクロアルジェコーポレーション株式会社 健康補助食品用軟カプセルの製法
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
JP2002516983A (ja) 1998-03-30 2002-06-11 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 核受容体活性を調節するための方法及び化合物
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
KR20010043455A (ko) 1998-06-30 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료용 약학적 조성물
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
EP1140186B1 (en) * 1998-12-23 2003-06-04 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US6914073B2 (en) * 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
WO2001019770A2 (en) 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2002333655A1 (en) 2001-09-25 2003-04-07 Smithkline Beecham Corporation Bicyclic heterocycles as rxr ligands
IN189624B (OSRAM) * 2001-10-23 2003-03-29 Ajanta Pharma Ltd
JP3978582B2 (ja) * 2001-12-19 2007-09-19 株式会社日健総本社 カロチノイドの製造方法
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor

Also Published As

Publication number Publication date
JP6490782B2 (ja) 2019-03-27
JP2013177457A (ja) 2013-09-09
US20050063991A1 (en) 2005-03-24
US7264813B2 (en) 2007-09-04
IL162987A (en) 2013-06-27
JP2009256392A (ja) 2009-11-05
JP2016147916A (ja) 2016-08-18
EP1522310A1 (en) 2005-04-13
EP2269620A1 (en) 2011-01-05
US7763255B2 (en) 2010-07-27
US20100221348A1 (en) 2010-09-02
JP2005097255A (ja) 2005-04-14
HK1071845A1 (en) 2005-08-05
US20080019997A1 (en) 2008-01-24
JP6321074B2 (ja) 2018-05-09
JP5356946B2 (ja) 2013-12-04
US8343549B2 (en) 2013-01-01
JP5020463B2 (ja) 2012-09-05
JP2018035200A (ja) 2018-03-08
EP1522310B1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
IL162987A (en) Pharmaceutical composition comprising dunaliella powder for treating diabetes, atherosclerosis and plasma lipid levels
PL1808168T3 (pl) Leczenie skojarzone cukrzycy i związanych z nią stanów oraz do leczenia stanów łagodzonych przez podwyższenie poziomu GLP-1 we krwi
WO2007124461A3 (en) Glp-1 compounds
WO2006083987A8 (en) Collaborative web page authoring
NO20065070L (no) Fremgangsmater for behandling av benkreftsmerte ved a administrere en nervevekstfaktorantagonist
WO2006027346A3 (en) Novel pyrazolopyrimidines
WO2004101752A3 (en) Compounds for treatment of inflammation, diabetes and related disorders
Mirone et al. Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica
AU2003251933A8 (en) Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
TW200741003A (en) Modulation of peroxisome proliferator-activated receptors
WO2006048877A3 (en) Treatment of b-cell malignancies with fgfr3 inhibitors
WO2006096740A3 (en) An apparatus and method for employing cloning for software development
DE60127713D1 (de) Insulinreinigung unter verwendung der simulierten wanderbett-technologie
Roane et al. Reduction of emergent dropping behavior during treatment of elopement
ZA200705470B (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
TW200607195A (en) Method of increasing surface work function of the ITO film by irradiation treatment of the excimer laser
ATE372990T1 (de) Oxazolderivat und deren verwendung als insulinsensibilisatoren
Lewy et al. The neurohormone melatonin as a marker, medicament, and mediator
Nicholas Anti-Aging Answers
Westkamp The limits of open source: lawful user rights, exhaustion and co-existence with copyright law
AU2003240254A1 (en) Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
Cordes et al. P02-98 Monitoring of the metabolic syndrome in psychiatric inpatients
DE602004021393D1 (de) Ladungssteuermittel mit einer mischung aus triphenylmethanverbindung und tetraphenylmethan
Zheng et al. Geochemical Factors Affecting Release of U (VI) from Soils
Szekely Children's Art Diary: Canvas Artists.